Patients ( tumor size > or = 3 cm , N0 to 2 , M0 ) were prospectively randomized to receive every 14 days a total of four cycles of doxorubicin 50 mg/m2 and docetaxel 75 mg/m ( 2 ) , either with ( ADocT ) or without ( ADoc ) simultaneous tamoxifen .
